Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 659,825 | 494,333 | 439,718 | 750,530 | 318,754 |
| Cost of Goods | 68,672 | 65,976 | 85,858 | 84,309 | 85,370 |
| Gross Profit | 591,153 | 428,357 | 353,860 | 666,221 | 233,384 |
| Operating Expenses | 543,211 | 472,768 | 471,122 | 452,663 | 463,585 |
| Operating Income | 48,614 | -43,435 | -116,404 | 213,867 | -229,831 |
| Interest Expense | 33,258 | 35,253 | 31,338 | 30,893 | 30,035 |
| Other Income | -26,523 | 15,101 | 10,055 | -32,233 | -14,343 |
| Pre-tax Income | -11,167 | -63,587 | -137,687 | 150,741 | -274,209 |
| Income Tax | 5,722 | 2,348 | 183 | 2,988 | 1,815 |
| Net Income Continuous | -16,889 | -65,935 | -137,870 | 147,753 | -276,024 |
| Net Income | $-16,889 | $-65,935 | $-137,870 | $147,753 | $-276,024 |
| EPS Basic Total Ops | -0.13 | -0.52 | -1.09 | 1.18 | -2.21 |
| EPS Basic Continuous Ops | -0.13 | -0.52 | -1.09 | 1.18 | -2.21 |
| EPS Diluted Total Ops | -0.13 | -0.52 | -1.06 | 1.15 | -2.21 |
| EPS Diluted Continuous Ops | -0.13 | -0.52 | -1.03 | 1.13 | -2.21 |
| EPS Diluted Before Non-Recurring Items | -0.13 | -0.52 | -1.10 | N/A | N/A |
| EBITDA(a) | $63,617 | $-29,918 | $-135,408 | $237,399 | $-206,384 |